Key clinical point: The paclitaxel, carboplatin, and capecitabine (TCX) regimen offers a good efficacy and safety profile in patients with advanced gastric cancer.

Major finding: The patients had a median progression-free survival (PFS) and overall survival (OS) of 9.3 and 17.0 months, respectively; the PFS rates were 74.6%, 32.5%, and 14.4% and OS rates were 97.5%, 68.7%, and 21.7% at 6 months, 1 year, and 2 years, respectively. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred only in 27.1%, 2.4%, and 1.2% of patients, respectively; non-hematologic and hematologic toxicities did not require intervention or treatment discontinuation.

Study details: This prospective cohort study included 83 patients with advanced gastric cancer who received the TCX regimen for ≥3 cycles.

Disclosures: No information on funding sources was provided. The author declared no conflicts of interest.

Source: Nguyen HT et al. Treatment outcome and safety of the TCX regimen for advanced gastric cancer: A prospective cohort study. Cancer Manag Res. 2022;14:2825-2837 (Sep 19). Doi: 10.2147/CMAR.S384325

Key clinical point: The paclitaxel, carboplatin, and capecitabine (TCX) regimen offers a good efficacy and safety profile in patients with advanced gastric cancer.

Major finding: The patients had a median progression-free survival (PFS) and overall survival (OS) of 9.3 and 17.0 months, respectively; the PFS rates were 74.6%, 32.5%, and 14.4% and OS rates were 97.5%, 68.7%, and 21.7% at 6 months, 1 year, and 2 years, respectively. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred only in 27.1%, 2.4%, and 1.2% of patients, respectively; non-hematologic and hematologic toxicities did not require intervention or treatment discontinuation.

Study details: This prospective cohort study included 83 patients with advanced gastric cancer who received the TCX regimen for ≥3 cycles.

Disclosures: No information on funding sources was provided. The author declared no conflicts of interest.

Source: Nguyen HT et al. Treatment outcome and safety of the TCX regimen for advanced gastric cancer: A prospective cohort study. Cancer Manag Res. 2022;14:2825-2837 (Sep 19). Doi: 10.2147/CMAR.S384325

Key clinical point: The paclitaxel, carboplatin, and capecitabine (TCX) regimen offers a good efficacy and safety profile in patients with advanced gastric cancer.

Major finding: The patients had a median progression-free survival (PFS) and overall survival (OS) of 9.3 and 17.0 months, respectively; the PFS rates were 74.6%, 32.5%, and 14.4% and OS rates were 97.5%, 68.7%, and 21.7% at 6 months, 1 year, and 2 years, respectively. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred only in 27.1%, 2.4%, and 1.2% of patients, respectively; non-hematologic and hematologic toxicities did not require intervention or treatment discontinuation.

Study details: This prospective cohort study included 83 patients with advanced gastric cancer who received the TCX regimen for ≥3 cycles.

Disclosures: No information on funding sources was provided. The author declared no conflicts of interest.

Source: Nguyen HT et al. Treatment outcome and safety of the TCX regimen for advanced gastric cancer: A prospective cohort study. Cancer Manag Res. 2022;14:2825-2837 (Sep 19). Doi: 10.2147/CMAR.S384325

Key clinical point: Some biologic disease-modifying antirheumatic drugs (bDMARDs), especially anti-tumor necrosis factor (TNF) agents, may prevent radiographic progression in patients with psoriatic arthritis (PsA).

Major finding: Anti-TNF agents like infliximab (standardized mean difference [SMD], −0.59; 95% CI, −0.87 to −0.3), etanercept (SMD, −0.51; 95% CI, −0.78 to −0.23), and adalimumab (SMD, −0.45; 95% CI, −0.64 to −0.26) followed by interleukin inhibitors like ixekizumab (SMD, −0.37; 95% CI, −0.62 to −0.12) and secukinumab 300 mg (SMD, −0.33; 95% CI, −0.50 to −0.15) were more effective than placebo in reducing the total radiographic score for structural damage.

Study details: Finding are from a meta-analysis of 11 randomized controlled trials including 4,010 patients with PsA who received bDMARDs or placebo.

Disclosures: This study did not receive any external funding. CH Yang declared receiving speaking fees from several sources.

Source: Wang SH et al. Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: A systematic review and network meta-analysis. Pharmaceutics. 2022;14(10):2140 (Oct 8). Doi: 10.3390/pharmaceutics14102140.

Key clinical point: Some biologic disease-modifying antirheumatic drugs (bDMARDs), especially anti-tumor necrosis factor (TNF) agents, may prevent radiographic progression in patients with psoriatic arthritis (PsA).

Major finding: Anti-TNF agents like infliximab (standardized mean difference [SMD], −0.59; 95% CI, −0.87 to −0.3), etanercept (SMD, −0.51; 95% CI, −0.78 to −0.23), and adalimumab (SMD, −0.45; 95% CI, −0.64 to −0.26) followed by interleukin inhibitors like ixekizumab (SMD, −0.37; 95% CI, −0.62 to −0.12) and secukinumab 300 mg (SMD, −0.33; 95% CI, −0.50 to −0.15) were more effective than placebo in reducing the total radiographic score for structural damage.

Study details: Finding are from a meta-analysis of 11 randomized controlled trials including 4,010 patients with PsA who received bDMARDs or placebo.

Disclosures: This study did not receive any external funding. CH Yang declared receiving speaking fees from several sources.

Source: Wang SH et al. Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: A systematic review and network meta-analysis. Pharmaceutics. 2022;14(10):2140 (Oct 8). Doi: 10.3390/pharmaceutics14102140.

Key clinical point: Some biologic disease-modifying antirheumatic drugs (bDMARDs), especially anti-tumor necrosis factor (TNF) agents, may prevent radiographic progression in patients with psoriatic arthritis (PsA).

Major finding: Anti-TNF agents like infliximab (standardized mean difference [SMD], −0.59; 95% CI, −0.87 to −0.3), etanercept (SMD, −0.51; 95% CI, −0.78 to −0.23), and adalimumab (SMD, −0.45; 95% CI, −0.64 to −0.26) followed by interleukin inhibitors like ixekizumab (SMD, −0.37; 95% CI, −0.62 to −0.12) and secukinumab 300 mg (SMD, −0.33; 95% CI, −0.50 to −0.15) were more effective than placebo in reducing the total radiographic score for structural damage.

Study details: Finding are from a meta-analysis of 11 randomized controlled trials including 4,010 patients with PsA who received bDMARDs or placebo.

Disclosures: This study did not receive any external funding. CH Yang declared receiving speaking fees from several sources.

Source: Wang SH et al. Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: A systematic review and network meta-analysis. Pharmaceutics. 2022;14(10):2140 (Oct 8). Doi: 10.3390/pharmaceutics14102140.

Key clinical point: Patients with psoriatic arthritis (PsA) reported a low cumulative incidence of opportunistic infections (OIs) after treatment with either biologic (bDMARDs) or targeted synthetic (tsDMARDs) disease-modifying antirheumatic drugs.

Major finding: The cumulative incidence of OIs was <3% when stratified by the mechanism of action: Janus Kinase inhibitors (2.72%; 95% CI, 1.05%-5.04%), anti-interleukin (IL)-17s (1.18%; 95% CI, 0.60%-1.90%), anti-IL-23s (0.24%; 95% CI, 0.04%-0.54%), and anti-tumor necrosis factors (0.01%; 95% CI, 0.00%-0.21%).

Study details: Findings are from a meta-analysis of 47 randomized controlled trials and 26 follow-up extension studies including patients with PsA who were assigned to receive ≥1 dose of bDMARD or tsDMARD (n=11,790) or placebo (n=6,425) during the placebo-controlled period; 17,197 patients received ≥1 dose of bDMARD or tsDMARD considering the extension period.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Vassilopoulos A et al. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis. Front. Pharmacol. 2022;13:992713 (Oct 5). Doi: 10.3389/fphar.2022.992713.

Key clinical point: Patients with psoriatic arthritis (PsA) reported a low cumulative incidence of opportunistic infections (OIs) after treatment with either biologic (bDMARDs) or targeted synthetic (tsDMARDs) disease-modifying antirheumatic drugs.

Major finding: The cumulative incidence of OIs was <3% when stratified by the mechanism of action: Janus Kinase inhibitors (2.72%; 95% CI, 1.05%-5.04%), anti-interleukin (IL)-17s (1.18%; 95% CI, 0.60%-1.90%), anti-IL-23s (0.24%; 95% CI, 0.04%-0.54%), and anti-tumor necrosis factors (0.01%; 95% CI, 0.00%-0.21%).

Study details: Findings are from a meta-analysis of 47 randomized controlled trials and 26 follow-up extension studies including patients with PsA who were assigned to receive ≥1 dose of bDMARD or tsDMARD (n=11,790) or placebo (n=6,425) during the placebo-controlled period; 17,197 patients received ≥1 dose of bDMARD or tsDMARD considering the extension period.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Vassilopoulos A et al. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis. Front. Pharmacol. 2022;13:992713 (Oct 5). Doi: 10.3389/fphar.2022.992713.

Key clinical point: Patients with psoriatic arthritis (PsA) reported a low cumulative incidence of opportunistic infections (OIs) after treatment with either biologic (bDMARDs) or targeted synthetic (tsDMARDs) disease-modifying antirheumatic drugs.

Major finding: The cumulative incidence of OIs was <3% when stratified by the mechanism of action: Janus Kinase inhibitors (2.72%; 95% CI, 1.05%-5.04%), anti-interleukin (IL)-17s (1.18%; 95% CI, 0.60%-1.90%), anti-IL-23s (0.24%; 95% CI, 0.04%-0.54%), and anti-tumor necrosis factors (0.01%; 95% CI, 0.00%-0.21%).

Study details: Findings are from a meta-analysis of 47 randomized controlled trials and 26 follow-up extension studies including patients with PsA who were assigned to receive ≥1 dose of bDMARD or tsDMARD (n=11,790) or placebo (n=6,425) during the placebo-controlled period; 17,197 patients received ≥1 dose of bDMARD or tsDMARD considering the extension period.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Vassilopoulos A et al. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis. Front. Pharmacol. 2022;13:992713 (Oct 5). Doi: 10.3389/fphar.2022.992713.

Key clinical point: Janus Kinase (JAK) inhibitors demonstrated promising efficacy in reducing disease severity in patients with psoriatic arthritis (PsA).

Major finding: Treatment with JAK inhibitors vs. placebo was associated with higher odds of achieving ≥20% improvement in American College of Rheumatology (ACR) score (odds ratio [OR], 4.45; 95% CI, 3.64-5.44), with similar outcomes observed with tofacitinib vs. placebo (OR, 2.96; 95% CI, 2.01-4.35) and non-tofacitinib JAK inhibitors vs. placebo (OR, 5.41; 95% CI, 3.95-7.40).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials including 6,757 patients with moderate-to-severe plaque psoriasis or PsA who received treatment with a JAK inhibitor or placebo.

Disclosures: S Sarabia declared receiving summer student grant from the Queen’s University Faculty of Medicine. The authors declared no conflicts of interest.

Source: Sarabia S et al. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol. 2022;6(1):71 (Sep 27). Doi: 10.1186/s41927-022-00287-7.

Key clinical point: Janus Kinase (JAK) inhibitors demonstrated promising efficacy in reducing disease severity in patients with psoriatic arthritis (PsA).

Major finding: Treatment with JAK inhibitors vs. placebo was associated with higher odds of achieving ≥20% improvement in American College of Rheumatology (ACR) score (odds ratio [OR], 4.45; 95% CI, 3.64-5.44), with similar outcomes observed with tofacitinib vs. placebo (OR, 2.96; 95% CI, 2.01-4.35) and non-tofacitinib JAK inhibitors vs. placebo (OR, 5.41; 95% CI, 3.95-7.40).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials including 6,757 patients with moderate-to-severe plaque psoriasis or PsA who received treatment with a JAK inhibitor or placebo.

Disclosures: S Sarabia declared receiving summer student grant from the Queen’s University Faculty of Medicine. The authors declared no conflicts of interest.

Source: Sarabia S et al. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol. 2022;6(1):71 (Sep 27). Doi: 10.1186/s41927-022-00287-7.

Key clinical point: Janus Kinase (JAK) inhibitors demonstrated promising efficacy in reducing disease severity in patients with psoriatic arthritis (PsA).

Major finding: Treatment with JAK inhibitors vs. placebo was associated with higher odds of achieving ≥20% improvement in American College of Rheumatology (ACR) score (odds ratio [OR], 4.45; 95% CI, 3.64-5.44), with similar outcomes observed with tofacitinib vs. placebo (OR, 2.96; 95% CI, 2.01-4.35) and non-tofacitinib JAK inhibitors vs. placebo (OR, 5.41; 95% CI, 3.95-7.40).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials including 6,757 patients with moderate-to-severe plaque psoriasis or PsA who received treatment with a JAK inhibitor or placebo.

Disclosures: S Sarabia declared receiving summer student grant from the Queen’s University Faculty of Medicine. The authors declared no conflicts of interest.

Source: Sarabia S et al. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol. 2022;6(1):71 (Sep 27). Doi: 10.1186/s41927-022-00287-7.

Key clinical point: Pain alleviation by tofacitinib in patients with psoriatic arthritis (PsA) was mostly due to improvement in itch, enthesitis, and C-reactive protein (CRP) levels.

Major finding: Tofacitinib predominantly reduced pain indirectly (70.5%; P < .0001), as indicated by improvements in the Itch Severity Item score (37.4%; P = .0002), Leeds Enthesitis Index score (17.8%; P = .0157), and CRP levels (15.3%; P = .0107).

Study details: Findings are from a mediation analysis of pooled data from 2 phase 3 studies (OPAL Broaden and OPAL Beyond) including 474 patients with active PsA who received tofacitinib 5 mg twice daily or placebo.

Disclosures: This study was funded by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and the other authors reported ties with several sources.

Source: de Vlam K et al. Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: A mediation analysis. Rheumatol Ther. 2022;9(5):1451-1464 (Sep 8). Doi: 10.1007/s40744-022-00482-5.

Key clinical point: Pain alleviation by tofacitinib in patients with psoriatic arthritis (PsA) was mostly due to improvement in itch, enthesitis, and C-reactive protein (CRP) levels.

Major finding: Tofacitinib predominantly reduced pain indirectly (70.5%; P < .0001), as indicated by improvements in the Itch Severity Item score (37.4%; P = .0002), Leeds Enthesitis Index score (17.8%; P = .0157), and CRP levels (15.3%; P = .0107).

Study details: Findings are from a mediation analysis of pooled data from 2 phase 3 studies (OPAL Broaden and OPAL Beyond) including 474 patients with active PsA who received tofacitinib 5 mg twice daily or placebo.

Disclosures: This study was funded by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and the other authors reported ties with several sources.

Source: de Vlam K et al. Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: A mediation analysis. Rheumatol Ther. 2022;9(5):1451-1464 (Sep 8). Doi: 10.1007/s40744-022-00482-5.

Key clinical point: Pain alleviation by tofacitinib in patients with psoriatic arthritis (PsA) was mostly due to improvement in itch, enthesitis, and C-reactive protein (CRP) levels.

Major finding: Tofacitinib predominantly reduced pain indirectly (70.5%; P < .0001), as indicated by improvements in the Itch Severity Item score (37.4%; P = .0002), Leeds Enthesitis Index score (17.8%; P = .0157), and CRP levels (15.3%; P = .0107).

Study details: Findings are from a mediation analysis of pooled data from 2 phase 3 studies (OPAL Broaden and OPAL Beyond) including 474 patients with active PsA who received tofacitinib 5 mg twice daily or placebo.

Disclosures: This study was funded by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and the other authors reported ties with several sources.

Source: de Vlam K et al. Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: A mediation analysis. Rheumatol Ther. 2022;9(5):1451-1464 (Sep 8). Doi: 10.1007/s40744-022-00482-5.

Key clinical point: Biologics improved disease activity (DA) in a real-world population of patients with psoriatic arthritis (PsA) in Italy.

Major finding: At 6 months, a substantially high proportion of patients receiving biologics achieved the European league against rheumatism (EULAR) DA Score 28 (71.8%; 95% CI, 66.7%-76.8%), with outcomes being similar with secukinumab (73.4%; 95% CI, 65.8%-81.1%) and tumor necrosis factor-inhibitors (71.9%; 95% CI, 64.9%-78.8%). The responder rate was 68.0% at year 1.

Study details: Findings are from a multicenter, noninterventional, cohort study including 399 patients with PsA, of which 308 were evaluable at 6 months and 297 patients were evaluable at 1 year. Most patients received biologics for ≥6 months.

Disclosures: This study was supported by a grant from Novartis Farma S.p.A. Origgio. Three authors declared being part-time/regular employees of Novartis Farma or MediNeos Observational Research, hired by Novartis Farma. The authors declared receiving honoraria, speaker fees, and/or scientific support from other sources.

Source: Colombo D et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: Results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: An ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol. 2022;6(1):57 (Sep 12). Doi: 10.1186/s41927-022-00284-w.

Key clinical point: Biologics improved disease activity (DA) in a real-world population of patients with psoriatic arthritis (PsA) in Italy.

Major finding: At 6 months, a substantially high proportion of patients receiving biologics achieved the European league against rheumatism (EULAR) DA Score 28 (71.8%; 95% CI, 66.7%-76.8%), with outcomes being similar with secukinumab (73.4%; 95% CI, 65.8%-81.1%) and tumor necrosis factor-inhibitors (71.9%; 95% CI, 64.9%-78.8%). The responder rate was 68.0% at year 1.

Study details: Findings are from a multicenter, noninterventional, cohort study including 399 patients with PsA, of which 308 were evaluable at 6 months and 297 patients were evaluable at 1 year. Most patients received biologics for ≥6 months.

Disclosures: This study was supported by a grant from Novartis Farma S.p.A. Origgio. Three authors declared being part-time/regular employees of Novartis Farma or MediNeos Observational Research, hired by Novartis Farma. The authors declared receiving honoraria, speaker fees, and/or scientific support from other sources.

Source: Colombo D et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: Results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: An ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol. 2022;6(1):57 (Sep 12). Doi: 10.1186/s41927-022-00284-w.

Key clinical point: Biologics improved disease activity (DA) in a real-world population of patients with psoriatic arthritis (PsA) in Italy.

Major finding: At 6 months, a substantially high proportion of patients receiving biologics achieved the European league against rheumatism (EULAR) DA Score 28 (71.8%; 95% CI, 66.7%-76.8%), with outcomes being similar with secukinumab (73.4%; 95% CI, 65.8%-81.1%) and tumor necrosis factor-inhibitors (71.9%; 95% CI, 64.9%-78.8%). The responder rate was 68.0% at year 1.

Study details: Findings are from a multicenter, noninterventional, cohort study including 399 patients with PsA, of which 308 were evaluable at 6 months and 297 patients were evaluable at 1 year. Most patients received biologics for ≥6 months.

Disclosures: This study was supported by a grant from Novartis Farma S.p.A. Origgio. Three authors declared being part-time/regular employees of Novartis Farma or MediNeos Observational Research, hired by Novartis Farma. The authors declared receiving honoraria, speaker fees, and/or scientific support from other sources.

Source: Colombo D et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: Results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: An ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol. 2022;6(1):57 (Sep 12). Doi: 10.1186/s41927-022-00284-w.

Key clinical point: Patients with psoriatic arthritis (PsA) who had nail psoriasis were older and had higher disease burden and lower quality of life (QoL) than those without nail psoriasis.

Major finding: Patients with vs. without nail psoriasis had a higher median age (48 vs. 46 years; P = .001), body mass index (29 vs. 28 kg/m²; P = .02), tender (P < .001) and swollen (P = .011) joint counts, and PsAQoL score (6 vs. 4; P = .001).

Study details: Findings are from a cross-sectional, multicenter study including 1,22 patients with PsA, of which 57.5% had nail psoriasis.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cengiz G et al. The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A cross-sectional multicenter study. Int J Rheum Dis. 2022 (Sep 27). Doi:10.1111/1756-185X.14442

Key clinical point: Patients with psoriatic arthritis (PsA) who had nail psoriasis were older and had higher disease burden and lower quality of life (QoL) than those without nail psoriasis.

Major finding: Patients with vs. without nail psoriasis had a higher median age (48 vs. 46 years; P = .001), body mass index (29 vs. 28 kg/m²; P = .02), tender (P < .001) and swollen (P = .011) joint counts, and PsAQoL score (6 vs. 4; P = .001).

Study details: Findings are from a cross-sectional, multicenter study including 1,22 patients with PsA, of which 57.5% had nail psoriasis.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cengiz G et al. The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A cross-sectional multicenter study. Int J Rheum Dis. 2022 (Sep 27). Doi:10.1111/1756-185X.14442

Key clinical point: Patients with psoriatic arthritis (PsA) who had nail psoriasis were older and had higher disease burden and lower quality of life (QoL) than those without nail psoriasis.

Major finding: Patients with vs. without nail psoriasis had a higher median age (48 vs. 46 years; P = .001), body mass index (29 vs. 28 kg/m²; P = .02), tender (P < .001) and swollen (P = .011) joint counts, and PsAQoL score (6 vs. 4; P = .001).

Study details: Findings are from a cross-sectional, multicenter study including 1,22 patients with PsA, of which 57.5% had nail psoriasis.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cengiz G et al. The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A cross-sectional multicenter study. Int J Rheum Dis. 2022 (Sep 27). Doi:10.1111/1756-185X.14442

Key clinical point: Patients with psoriatic arthritis (PsA) and obesity had ~50% lower likelihood of achieving minimal disease activity (MDA) or remission within a year of initiating treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD).

Major finding: Odds of achieving MDA (adjusted odds ratio [aOR] 0.45; 95% CI 0.24-0.82) and DAPSA-remission (aOR 0.42; 95% CI 0.21-0.85) were lower in the obese vs normal weight group within the first year; similarly, the overweight group had reduced odds of achieving DAPSA-remission (aOR 0.44; 95% CI 0.24-0.79).

Study details: Findings are from an observational cohort study including 774 adult patients with PsA who started their first b/tsDMARD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Vallejo-Yague E et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474 (Sep 17). Doi: 10.1136/bmjopen-2022-061474

Key clinical point: Patients with psoriatic arthritis (PsA) and obesity had ~50% lower likelihood of achieving minimal disease activity (MDA) or remission within a year of initiating treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD).

Major finding: Odds of achieving MDA (adjusted odds ratio [aOR] 0.45; 95% CI 0.24-0.82) and DAPSA-remission (aOR 0.42; 95% CI 0.21-0.85) were lower in the obese vs normal weight group within the first year; similarly, the overweight group had reduced odds of achieving DAPSA-remission (aOR 0.44; 95% CI 0.24-0.79).

Study details: Findings are from an observational cohort study including 774 adult patients with PsA who started their first b/tsDMARD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Vallejo-Yague E et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474 (Sep 17). Doi: 10.1136/bmjopen-2022-061474

Key clinical point: Patients with psoriatic arthritis (PsA) and obesity had ~50% lower likelihood of achieving minimal disease activity (MDA) or remission within a year of initiating treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD).

Major finding: Odds of achieving MDA (adjusted odds ratio [aOR] 0.45; 95% CI 0.24-0.82) and DAPSA-remission (aOR 0.42; 95% CI 0.21-0.85) were lower in the obese vs normal weight group within the first year; similarly, the overweight group had reduced odds of achieving DAPSA-remission (aOR 0.44; 95% CI 0.24-0.79).

Study details: Findings are from an observational cohort study including 774 adult patients with PsA who started their first b/tsDMARD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Vallejo-Yague E et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474 (Sep 17). Doi: 10.1136/bmjopen-2022-061474

Key clinical point: Preliminary results from this real-world study demonstrated efficacy of interleukin (IL)-23 inhibitors in patients with psoriatic arthritis (PsA).

Major finding: A substantial proportion of patients with PsA receiving either of the IL-23 inhibitors achieved complete (40.9%) or partial (36.4%) remission compared with only 18.2% of patients who demonstrated no improvement. A higher proportion of patients receiving guselkumab achieved remission or partial remission (38.5% and 46.1%, respectively) than treatment failure (15.4%), with similar outcomes being observed with risankizumab.

Study details: Findings are from a retrospective, observational study including 80 patients with psoriasis who received guselkumab, tildrakizumab, or risankizumab, of which 27.5% of patients had PsA.

Disclosures: This study did not receive any funding. The authors declared serving as consultants, paid speakers, and/or advisors and/or receiving speaking fees or grants from several sources.

Source: Elgaard CDB et al. Guselkumab, tildrakizumab and risankizumab in real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022;1-24 (Oct 6). Doi: 10.1080/09546634.2022.2133531.

Key clinical point: Preliminary results from this real-world study demonstrated efficacy of interleukin (IL)-23 inhibitors in patients with psoriatic arthritis (PsA).

Major finding: A substantial proportion of patients with PsA receiving either of the IL-23 inhibitors achieved complete (40.9%) or partial (36.4%) remission compared with only 18.2% of patients who demonstrated no improvement. A higher proportion of patients receiving guselkumab achieved remission or partial remission (38.5% and 46.1%, respectively) than treatment failure (15.4%), with similar outcomes being observed with risankizumab.

Study details: Findings are from a retrospective, observational study including 80 patients with psoriasis who received guselkumab, tildrakizumab, or risankizumab, of which 27.5% of patients had PsA.

Disclosures: This study did not receive any funding. The authors declared serving as consultants, paid speakers, and/or advisors and/or receiving speaking fees or grants from several sources.

Source: Elgaard CDB et al. Guselkumab, tildrakizumab and risankizumab in real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022;1-24 (Oct 6). Doi: 10.1080/09546634.2022.2133531.

Key clinical point: Preliminary results from this real-world study demonstrated efficacy of interleukin (IL)-23 inhibitors in patients with psoriatic arthritis (PsA).

Major finding: A substantial proportion of patients with PsA receiving either of the IL-23 inhibitors achieved complete (40.9%) or partial (36.4%) remission compared with only 18.2% of patients who demonstrated no improvement. A higher proportion of patients receiving guselkumab achieved remission or partial remission (38.5% and 46.1%, respectively) than treatment failure (15.4%), with similar outcomes being observed with risankizumab.

Study details: Findings are from a retrospective, observational study including 80 patients with psoriasis who received guselkumab, tildrakizumab, or risankizumab, of which 27.5% of patients had PsA.

Disclosures: This study did not receive any funding. The authors declared serving as consultants, paid speakers, and/or advisors and/or receiving speaking fees or grants from several sources.

Source: Elgaard CDB et al. Guselkumab, tildrakizumab and risankizumab in real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022;1-24 (Oct 6). Doi: 10.1080/09546634.2022.2133531.

Key clinical point: Guselkumab demonstrated promising efficacy and was well tolerated in a real-world population of patients with psoriatic arthritis (PsA) and psoriasis.

Major finding: Before starting guselkumab, 48% of patients had moderate/high disease activity in PsA (DAPSA). In this subgroup, the mean DAPSA score reduced from 29 to 20, 16, and 14 at weeks 12, 24, and 52, respectively (P < .0001). Only 2.2% of patients reported mild adverse events.

Study details: Findings are from a multicenter, retrospective, observational study including 90 patients with PsA and concomitant psoriasis who started treatment with guselkumab.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rocamora V et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022 (Sep 29). Doi: 10.1111/dth.15865

Key clinical point: Guselkumab demonstrated promising efficacy and was well tolerated in a real-world population of patients with psoriatic arthritis (PsA) and psoriasis.

Major finding: Before starting guselkumab, 48% of patients had moderate/high disease activity in PsA (DAPSA). In this subgroup, the mean DAPSA score reduced from 29 to 20, 16, and 14 at weeks 12, 24, and 52, respectively (P < .0001). Only 2.2% of patients reported mild adverse events.

Study details: Findings are from a multicenter, retrospective, observational study including 90 patients with PsA and concomitant psoriasis who started treatment with guselkumab.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rocamora V et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022 (Sep 29). Doi: 10.1111/dth.15865

Key clinical point: Guselkumab demonstrated promising efficacy and was well tolerated in a real-world population of patients with psoriatic arthritis (PsA) and psoriasis.

Major finding: Before starting guselkumab, 48% of patients had moderate/high disease activity in PsA (DAPSA). In this subgroup, the mean DAPSA score reduced from 29 to 20, 16, and 14 at weeks 12, 24, and 52, respectively (P < .0001). Only 2.2% of patients reported mild adverse events.

Study details: Findings are from a multicenter, retrospective, observational study including 90 patients with PsA and concomitant psoriasis who started treatment with guselkumab.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rocamora V et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022 (Sep 29). Doi: 10.1111/dth.15865